Latest Healthcare It News

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.

Enlitic has locked in binding commitments for a conditional A$15 million capital raise alongside a convertible note conversion, setting the stage for a clearer path to cashflow break-even and accelerated rollout of its SaaS platform.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

OncoSil Medical has submitted its Humanitarian Device Exemption application to the FDA for its OncoSil™ device targeting distal cholangiocarcinoma, entering the final review phase with a decision expected within 45 days.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.

Archer Materials has secured a three-year strategic deal with IonQ, the global quantum computing leader, gaining access to advanced quantum cloud services and exploring onshore deployment of quantum hardware in Australia.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

Enlitic has landed its inaugural Australian Ensight subscription contract with Lumus Imaging, marking a strategic entry into the local SaaS market and expanding its footprint in diagnostic imaging workflows.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.